Companies › Genmab A/s

Genmab A/s (GMAB): Financial Statements and Key Figures

Genmab A/s (ticker GMAB) is classified by the SEC under industry code 2834, Pharmaceutical Preparations, and is listed on Nasdaq. It files its annual report with the U.S. Securities and Exchange Commission (SEC) on Form 20-F and reports in US dollars. Its fiscal 2025 ended on 31 December 2025; the annual report for that year was filed on 17 February 2026. For that year it reported revenue of US$ 3,720 million, net income of US$ 963 million and total assets of US$ 12,873 million at the year end. Fiscal years 2018 to 2025 are shown below (fiscal 2020, 2021, 2022 is not on file).

The figures are as the company filed them, standardised by reporting tag; the filing is the authority. For education and analysis, not investment advice.

Key Figures

Money in millions of the currency named under each year; earnings per share in that currency. Free cash flow is the cash from operating activities less capital expenditures. Total debt is short-term plus long-term debt, or the total the company itself tags when that is larger. A margin is the profit line divided by revenue; return on equity is net income divided by the average of shareholders' equity at the start and the end of the year. A blank cell means the company does not report the line under a standard tag; it does not mean zero.

Last twelve months: not shown. No quarterly reports in XBRL (the company files annual, half-year or current reports only): no last-twelve-month figures, none estimated.

Charts

Figure 1: Revenue and net income by fiscal year (millions, currency as filed each year)

Figure 2: Cash from operating activities and free cash flow by fiscal year (millions, currency as filed each year)

Compound Growth

The compound annual growth rate is the single yearly rate that, applied every year, takes the first value to the last one: the last value divided by the first, raised to the power of one over the number of years, less one. It uses only the two end values, so an unusual first or last year moves it a great deal. This company changed its reporting currency during the years shown, so a rate across the change mixes two currencies.

• Revenue: 3,025 in fiscal 2018 to 3,720 in fiscal 2025 (millions), 7 years: 3.0 % a year.
• Diluted earnings per share: 23.73 in fiscal 2018 to 15.37 in fiscal 2025 (currency as filed per share), 7 years: −6.0 % a year.

Analyse This Company

Each link opens a calculator with Genmab A/s loaded from the same data.

• Company Financial Statements: The full income statement, balance sheet and cash flow statement of each fiscal year, with common-size and growth views.
• Capital Allocation History: Where the cash from operations went each year: capital expenditures, dividends, share repurchases, debt.
• Dividend Sustainability: How the dividends paid compare with earnings and with free cash flow, year by year.
• Earnings Quality Trend: How much of reported earnings arrived as cash, and how accruals moved over the years.
• Reverse DCF: The growth in free cash flow that a share price you type would assume.
• Financial Quality Scores: The Piotroski F-score and the DuPont breakdown of return on equity, worked step by step.
• Valuation Range: What a share price you type corresponds to as multiples of earnings, cash flow and book value, against the company's own history.

Several companies at once: Peer Comparison and Fundamental Screener.

Same Industry

The first 12 in alphabetical order of the 24 other companies in the data with the industry code 2834 (Pharmaceutical Preparations), in alphabetical order; the index lists every company.

• Abbott Laboratories (ABT)
• AbbVie Inc. (ABBV)
• Alnylam Pharmaceuticals, Inc. (ALNY)
• Astrazeneca plc (AZN)
• BeOne Medicines Ltd. (ONC)
• Bristol Myers Squibb Co (BMY)
• ELI LILLY & Co (LLY)
• GSK plc (GSK)
• INSMED Inc (INSM)
• Johnson & Johnson (JNJ)
• Merck & Co., Inc. (MRK)
• Novartis AG (NVS)

Source

The annual report first filed for each fiscal year, with a link to its index page on EDGAR, the SEC's filing system. A later annual report repeats earlier years for comparison and sometimes restates them; where a value was taken from a later report, the last column gives the date of the latest one used.

• The figures are as filed with the SEC and standardised by reporting tag. The filing is the authority: check it before relying on a number.
• A blank cell means the company does not tag that line, or the tagged figure is withheld as incomplete. It does not mean zero.
• Currency: every figure is in the currency the company reported that year (DKK, USD here). Nothing is converted. The reporting currency changed: fiscal 2018 to 2019 in DKK, fiscal 2023 to 2025 in USD.
• Per-share figures are adjusted for stock splits detected from the company's own restated figures, except where a year is flagged; the as-filed values are in the filings.
• For a bank, broker, insurer or other financial company (SIC codes 6000 to 6799) net debt, EBITDA, the current ratio and debt to equity are not meaningful and the tools show them as n/m.
• A fiscal year is named after the calendar year in which it ends. The data is updated from time to time, not daily; this company's figures were loaded on 13 November 2026.

For education and analysis, not investment advice.